Blu – Pagina 136

Giugno 16, 2023 dario.olivero

The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes

Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Frigé C, De Cosmo S, Di Bartolo P, Di Cianni G, Fioretto P, Giorda CB, Pontremoli R, Russo G, Viazzi F, Nicolucci A
The Lancet Regional Health-Europe. Pub. online 12 Jun 2023.

Leggi

Giugno 13, 2023 dario.olivero

Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes

Pratt E, Ma X, Liu R, et al.
Diabetes Obes Metab. Pub. online 1 Jun 2023.

Leggi

Giugno 13, 2023 dario.olivero

Genetic evidence that high BMI in childhood has a protective effect on intermediate diabetes traits, including measures of insulin sensitivity and secretion, after accounting for BMI in adulthood

Hawkes G, Beaumont RN, Tyrrell J, et al.
Diabetologia. Pub. online 6 Jun 2023.

Leggi

Giugno 13, 2023 dario.olivero

Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in Diabetic patients with Acute Myocardial Infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT Registry

Paolisso P, Bergamaschi L, Cesaro A, et al.
Diabetes Res Clin Pract. 2023;110766.

Leggi

Giugno 13, 2023 dario.olivero

Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy – a comprehensive cancer center experience

Zhang Z, Sharma R, Hamad LA, et al.
Diabetes Res Clin Pract. Pub. online 10 Jan 2023.

Leggi

Giugno 13, 2023 dario.olivero

The Type 1 Diabetes and EXercise Initiative (T1DEXI): predicting hypoglycemia risk during exercise for participants with type 1 diabetes using repeated measures random forest

Bergford S, Riddell MC, Jacobs PG, et al.
Diabetes Technol Ther. Pub. online 9 Jun 2023.

Leggi

Giugno 13, 2023 dario.olivero

Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial

Hundertmark MJ, Adler A, Antoniades C, et al.
Circulation. 2023;147(22):1654-1669.

Leggi

Giugno 12, 2023 dario.olivero

The burden of obesity in type 1 diabetic subjects: a sex-specific analysis from the AMD Annals Initiative

Giandalia A, Russo GT, Ruggeri P, et al.
J Clin Endocrinol Metab. 2023;dgad302.

Leggi

Giugno 7, 2023 dario.olivero

Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes

Stougaard EB, Rossing P, Vistisen D, et al.
Diabetes Obes Metab. 2023;25(7):1874-1882.

Leggi

Giugno 7, 2023 dario.olivero

Stabilization of kidney function and reduction in heart failure events with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis and meta‐regression analysis

Keidai Y, Yoshiji S, Hasebe M, et al.
Diabetes Obes Metab. Pub. online 22 May 2023.

Leggi